The COVID-19 treatmentsAntivirals and clinicalTherapeutics trialsTaskforce
DHSCThe publicationsDHSC-led relatingCOVID-19 toAntivirals COVID-19and Therapeutics Taskforce co-ordinates the end-to-end provision of treatments for coronavirus (COVID-19) in the UK so patients get access to safe and clinicaleffective trials.treatments as soon as possible.
The COVID-19 Antivirals and Therapeutics Taskforce
ThisThe collectionCOVID-19 bringsAntivirals togetherand publicationsTherapeutics fromTaskforce is responsible for the Departmentend-to-end provision of Healthtreatments andfor Socialcoronavirus Care(COVID-19) (DHSCin the UK).
The relatingtaskforce tois coronavirusresponsible (COVID-19)for:
identifyingpotentialCOVID-19therapeuticstriallingtheseaspartofanadvancedprogrammeofclinicaltrialsdeployingeffectivetoUKpatients
The taskforce works with industry experts to identify, develop and clinicalprocure trials.novel oral antivirals (those in pill or tablet form) that patients can take promptly following infection.
Contact details
Email: attf@dhsc.gov.uk
For morefreedom information,of see:information requests, please contact DHSC.
Further information
-
treatments
UrgentforPublicCOVID-19Healthmembership NationalonInstitutetheforNHSHealthwebsiteandCareResearch(NIHR) fundedresearchintoCOVID-19NIHR’sresponsetoMedicinesTherapeuticsandClinicalHealthcareReviewproductsPanelRegulatoryAgency(MHRA) guidanceoncoronavirus(COVID-19)
ExpertAccess adviceto community treatments
TreatmentsClinical trials
Protection
The Antivirals and Therapeutics Taskforce has worked with key stakeholders to explore new and improved methods of preventing COVID-19, including funding research.
PROTECT-V is a phase 3 trial testing prophylactic interventions for COVID-19 in vulnerable renal and immunocompromised patients.
Prophylactic medicines may be administered as a preventative treatment to help reduce the risk of severe COVID-19 disease among the most vulnerable groups.
The ‘Evaluation of preventative medicines’, linked to below, gives information on clinical deployment decisions on preventative medicines.
Clinical trials
Last updated 31
-
Renamed and updated document collection to reflect the closure of the Antivirals and Therapeutics Taskforce on 31 March 2023.
-
Added information under 'Protection' including a link to the Evusheld evaluation.
-
Added new 'Protection' section containing links to pages on the RAPID C-19 Oversight Group report into Evusheld and letter to patient groups on the decision not to procure Evusheld.
-
First published.
Update history
2023-05-25 14:10
Added ‘Higher-risk patients eligible for COVID-19 treatments: independent advisory group report (March 2023)’ to the expert advice section.
2023-03-31 14:14
Renamed and updated document collection to reflect the closure of the Antivirals and Therapeutics Taskforce on 31 March 2023.
2022-12-14 15:15
Added information under ‘Protection’ including a link to the Evusheld evaluation.
2022-10-06 14:00
Added new ‘Protection’ section containing links to pages on the RAPID C-19 Oversight Group report into Evusheld and letter to patient groups on the decision not to procure Evusheld.
2022-09-06 12:22
First published.